Biodegradable Polymer Intraocular Implants for Sustained Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional treatments for glaucoma, such as daily eye drops, have low patient compliance and can lead to eye infections due to improper use, necessitating a long-term, sustained release treatment for elevated intraocular pressure.
Innovation Solution
A sustained release intraocular drug delivery system comprising an antihypertensive agent and a biodegradable polymer, administered intracameral or anterior vitreously, in the form of implants or microspheres, which provide extended release of therapeutic agents like prostaglandins to treat elevated intraocular pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional eye drops are used for daily treatment, then intraocular pressure can be reduced, but patient compliance is low and eye infections may occur
Solution Approach 1:
The treatment is segmented into a single intraocular administration event that delivers the drug in divided, controlled releases over time, eliminating the need for repeated daily applications by patients
Solution Approach 2:
The implant performs self-service by automatically releasing the drug at controlled rates over an extended period without requiring patient intervention, thereby ensuring consistent treatment effectiveness while eliminating compliance issues
2Reliability
If sustained release implants are administered intracameral, then drug delivery is improved and systemic exposure is reduced, but the procedure requires surgical intervention
Solution Approach 1:
The implant acts as an intermediary device that bridges the gap between surgical intervention and non-invasive drug delivery, providing a minimally invasive approach that achieves sustained release without requiring complex surgical procedures or repeated interventions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively reduces intraocular pressure by 20-50% for several weeks to months, improving compliance and minimizing side effects by bypassing transscleral barriers and reducing systemic drug exposure.
Implementation Method 1
The implant releases therapeutically effective amounts of the anti-hypertensive agent over an extended period of time
Implementation Method 2
a biodegradable polymer for use in a method for treating elevated intraocular pressure
Data Source
Figure 1
Figure 2
Figure 3A~3D
AI summary
Biocompatible, bioerodible sustained release implants and microspheres for intracameral or anterior vitreal placement include an anti-hypertensive agent and a biodegradable polymer effective to treat an ocular hypertensive condition (such as glaucoma) by relapsing therapeutic amount of the anti-hypertensive agent over a period of time between 10 days and 1 year.